

Current Lung-MAP Schema

Biomarker-Driven Sub-Studies

Non-Match Sub-Studies

Completed 12/12/16
Completed 09/01/16
Completed 10/31/16
Closed 11/25/14

S1400B
PI3K+

S1400C
CCGA+*

S1400D
FGFR+

S1400E
c-Met

S1400G
HRRD+*

Upcoming

S1400K
c-Met+

Completed 12/18/15

S1400A
Non-match

S1400I
Checkpoint Naive

S1400F
Checkpoint Refractory

Taselisib

Palbociclib

AZD4547

Rilotumumab
/Erlotinib

Erlotinib

Talazoparib

Telisotuzumab
Vedotin

Durvalumab

Nivolumab/
Ipilimumab

Nivolumab

Durvalumab/
Tremelimumab



Future Re-Design

Previously-treated Stage IV or Recurrent
Non-Small Cell Lung Cancer
(All Histology)
Immunotherapy or Chemotherapy Relapsed/Refractory Patients

Biomarker-Driven Sub-Studies

Non-Match Sub-Studies

Biomarker 1 Positive

Biomarker n Positive

IO Naïve (Squamous O-only)

IO Relapsed/Refractory

Sub-study 1 Biomarker-driven Therapy

Sub-study n Biomarker-Driven Therapy

Nivolumab + Ipilimumab vs Nivolumab

Collect Tissue for Immuno Biomarker Profiling

Investigational Therapy 1

Investigational Therapy n

S1400I

Randomization

Investigational Therapy 1

Standard of Care


Investigational Therapy n

Standard of Care

IO Sub-Study 1 IO Combo 1

IO Sub-Study m IO Combo m

Common Control Dealer's Choice Based on Histology





Real Change, Real Benefits

- **Enrollment Efficiency:** Grouping these studies under a single trial reduces the overall failure rate for patient biomarker screening
- **Operational Efficiency:** Single master protocol can be amended as needed as drugs enter and exit the study
- **Consistency:** Every drug entered into the trial will be tested in the identical manner
- **Predictability:** If pre-specified efficacy and safety criteria are met, the drug and accompanying companion diagnostic will be approved
- **Patient Benefit:** Brings safe and effective drugs to patients sooner than they might otherwise be available.